BB Biotech AG (BION.SW)
CHF 28.45
(4.4%)
CHF 28.45
(4.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.63 Billion CHF | -13.63% |
| 2022 | 3.05 Billion CHF | -16.21% |
| 2021 | 3.64 Billion CHF | -8.05% |
| 2020 | 3.96 Billion CHF | 11.49% |
| 2019 | 3.55 Billion CHF | 15.15% |
| 2018 | 3.08 Billion CHF | -15.15% |
| 2017 | 3.63 Billion CHF | 12.76% |
| 2016 | 3.22 Billion CHF | -22.14% |
| 2015 | 4.14 Billion CHF | 17.29% |
| 2014 | 3.53 Billion CHF | 59.79% |
| 2013 | 2.21 Billion CHF | 60.91% |
| 2012 | 1.37 Billion CHF | 19.31% |
| 2011 | 1.15 Billion CHF | -16.37% |
| 2010 | 1.37 Billion CHF | -9.46% |
| 2009 | 1.52 Billion CHF | -6.07% |
| 2008 | 1.61 Billion CHF | -22.04% |
| 2007 | 2.07 Billion CHF | -18.67% |
| 2006 | 2.55 Billion CHF | 2.22% |
| 2005 | 2.49 Billion CHF | 30.25% |
| 2004 | 1.91 Billion CHF | -3.26% |
| 2003 | 1.98 Billion CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.7 Billion CHF | -4.19% |
| 2024 Q3 | 2.5 Billion CHF | -7.5% |
| 2024 Q1 | 2.82 Billion CHF | 7.24% |
| 2023 Q3 | 2.52 Billion CHF | -2.24% |
| 2023 Q4 | 2.63 Billion CHF | 4.62% |
| 2023 FY | 2.63 Billion CHF | -13.63% |
| 2023 Q1 | 2.59 Billion CHF | -15.0% |
| 2023 Q2 | 2.57 Billion CHF | -0.65% |
| 2022 Q3 | 3.02 Billion CHF | 6.09% |
| 2022 Q1 | 3.12 Billion CHF | -14.37% |
| 2022 FY | 3.05 Billion CHF | -16.21% |
| 2022 Q2 | 2.85 Billion CHF | -8.53% |
| 2022 Q4 | 3.05 Billion CHF | 0.83% |
| 2021 Q3 | 4.09 Billion CHF | -6.02% |
| 2021 FY | 3.64 Billion CHF | -8.05% |
| 2021 Q1 | 4.28 Billion CHF | 8.07% |
| 2021 Q2 | 4.35 Billion CHF | 1.73% |
| 2021 Q4 | 3.64 Billion CHF | -11.01% |
| 2020 FY | 3.96 Billion CHF | 11.49% |
| 2020 Q3 | 3.48 Billion CHF | -9.14% |
| 2020 Q2 | 3.83 Billion CHF | 37.41% |
| 2020 Q1 | 2.78 Billion CHF | -21.57% |
| 2020 Q4 | 3.96 Billion CHF | 13.87% |
| 2019 Q4 | 3.55 Billion CHF | 0.0% |
| 2019 FY | 3.55 Billion CHF | 15.15% |
| 2019 Q2 | 3.64 Billion CHF | -8.6% |
| 2019 Q1 | 3.98 Billion CHF | 29.18% |
| 2018 Q2 | 3.65 Billion CHF | -1.03% |
| 2018 Q4 | 3.08 Billion CHF | -20.02% |
| 2018 FY | 3.08 Billion CHF | -15.15% |
| 2018 Q1 | 3.68 Billion CHF | 1.41% |
| 2018 Q3 | 3.85 Billion CHF | 5.71% |
| 2017 Q3 | 3.71 Billion CHF | 10.47% |
| 2017 FY | 3.63 Billion CHF | 12.76% |
| 2017 Q1 | 3.53 Billion CHF | 9.46% |
| 2017 Q2 | 3.35 Billion CHF | -4.88% |
| 2017 Q4 | 3.63 Billion CHF | -1.97% |
| 2016 Q3 | 3.25 Billion CHF | 9.35% |
| 2016 Q2 | 2.97 Billion CHF | 0.86% |
| 2016 FY | 3.22 Billion CHF | -22.14% |
| 2016 Q4 | 3.22 Billion CHF | -0.93% |
| 2016 Q1 | 2.95 Billion CHF | -28.75% |
| 2015 Q2 | 4.06 Billion CHF | 8.58% |
| 2015 Q3 | 3.55 Billion CHF | -12.7% |
| 2015 Q4 | 4.14 Billion CHF | 16.65% |
| 2015 Q1 | 3.74 Billion CHF | 6.08% |
| 2015 FY | 4.14 Billion CHF | 17.29% |
| 2014 Q4 | 3.53 Billion CHF | 20.51% |
| 2014 Q3 | 2.93 Billion CHF | 18.33% |
| 2014 FY | 3.53 Billion CHF | 59.79% |
| 2014 Q1 | 2.28 Billion CHF | 3.28% |
| 2014 Q2 | 2.47 Billion CHF | 8.5% |
| 2013 Q4 | 2.21 Billion CHF | 1.25% |
| 2013 Q1 | 1.67 Billion CHF | 22.27% |
| 2013 Q2 | 1.78 Billion CHF | 6.19% |
| 2013 Q3 | 2.18 Billion CHF | 22.41% |
| 2013 FY | 2.21 Billion CHF | 60.91% |
| 2012 FY | 1.37 Billion CHF | 19.31% |
| 2012 Q4 | 1.37 Billion CHF | -11.04% |
| 2012 Q3 | 1.54 Billion CHF | 9.99% |
| 2012 Q2 | 1.4 Billion CHF | 13.81% |
| 2012 Q1 | 1.23 Billion CHF | 7.13% |
| 2011 Q3 | 1.05 Billion CHF | -17.38% |
| 2011 Q4 | 1.15 Billion CHF | 9.45% |
| 2011 Q1 | 1.35 Billion CHF | -1.46% |
| 2011 FY | 1.15 Billion CHF | -16.37% |
| 2011 Q2 | 1.27 Billion CHF | -6.15% |
| 2010 Q1 | 1.53 Billion CHF | 1.2% |
| 2010 Q2 | 1.35 Billion CHF | -11.68% |
| 2010 Q3 | 1.32 Billion CHF | -2.31% |
| 2010 Q4 | 1.37 Billion CHF | 3.7% |
| 2010 FY | 1.37 Billion CHF | -9.46% |
| 2009 FY | 1.52 Billion CHF | -6.07% |
| 2009 Q4 | 1.52 Billion CHF | 0.0% |
| 2008 FY | 1.61 Billion CHF | -22.04% |
| 2007 FY | 2.07 Billion CHF | -18.67% |
| 2006 FY | 2.55 Billion CHF | 2.22% |
| 2005 FY | 2.49 Billion CHF | 30.25% |
| 2004 FY | 1.91 Billion CHF | -3.26% |
| 2003 FY | 1.98 Billion CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Addex Therapeutics Ltd | 4.64 Million CHF | -56722.516% |
| Basilea Pharmaceutica AG | 173.28 Million CHF | -1421.824% |
| Evolva Holding SA | 9.82 Million CHF | -26732.523% |
| Idorsia Ltd | 499.99 Million CHF | -427.435% |
| Kuros Biosciences AG | 75.9 Million CHF | -3374.237% |
| Molecular Partners AG | 198.35 Million CHF | -1229.532% |
| Relief Therapeutics Holding AG | 76.39 Million CHF | -3352.224% |
| Santhera Pharmaceuticals Holding AG | 109.62 Million CHF | -2305.526% |